- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07949591
Foxtail Millet (Setaria Italica (L.) P. Beauv.)-Based Diet on Postprandial Glycemic Control in Adults With Obesity and Type 2 Diabetes
This 10-week randomized controlled trial evaluated the nutritional quality and dose-specific effects of foxtail millet muffins (50 and 100 g/day) alongside a low-glycemic index diet among 102 obese adults with T2DM. The study will assess changes in glycemic control, lipid profile, liver function, and anthropometric parameters to investigate the potential of foxtail millet as a functional dietary intervention for diabetes management.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This 10-week randomized controlled trial investigated the nutritional quality and potential health benefits of foxtail millet (Setaria italica) muffins among 102 obese adults with type 2 diabetes mellitus (T2DM). Participants were randomly allocated into three groups: placebo (wheat muffin, T₀), low-dose foxtail millet muffin (50 g/day, T₁), and high-dose foxtail millet muffin (100 g/day, T₂), with all groups following a standardized low-glycemic index diet. The nutritional composition, including proximate constituents and mineral content, and sensory acceptability of the muffins were evaluated using standard AOAC procedures and a 9-point hedonic scale. Anthropometric measurements, including body weight, BMI, and other relevant parameters, were assessed alongside fasting blood glucose (FBG), glycated hemoglobin (HbA1c), lipid profile, and liver function biomarkers at baseline and after the intervention. The study aimed to determine whether daily consumption of foxtail millet-based muffins could provide a nutritionally valuable dietary option and support improvements in glycemic regulation, metabolic health, and anthropometric status among obese adults with T2DM.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: SANA NOREEN, PhD
- Telefonnummer: 03018661160
- E-post: SANA.NOREEN@DNSC.UOL.EDU.PK
Studieorter
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Sana Noreen
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- People between 30 to 60 years old.
- Body Mass Index (BMI) ≥30.0 kg/m².
- Fasting blood glucose levels ≥ 7.0 mmol/L (126 mg/dL).
- Individuals having HbA1c ≥ 6.5%.
- Elevated Lipid Profile: TC > 200 mg/dL, TG > 150 mg/dL, LDL-C > 100 mg/dL, HDL-C < 40 mg/dL (men) / < 50 mg/dL (women).
- Elevated Liver Function Tests: ALT > 56 U/L, AST > 40 U/L, ALP > 147 U/L, Total Bilirubin > 1.2 mg/dL, Albumin < 3.5 g/dL.
Exclusion Criteria:
- Individuals who have a known allergy or have experienced any adverse reaction to foxtail millet or any of the ingredients used in the muffins will not be included in the study.
- Patients who are taking medications known to significantly alter glucose metabolism or gastrointestinal absorption.
- Individuals who have recently had gastric surgery or who have surgery planned during the research period.
- Presence of other severe chronic diseases (e.g., severe renal, hepatic, or cardiovascular disease, active cancer).
- Nursing or pregnant females.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: PLACEBO T0
T₀; wheat muffin |
wheat muffin |
|
Experimentell: Intervention Group (T₁)
low-dose foxtail millet muffin (T₁; 50 g/day) |
low-dose foxtail millet muffin (T₁; 50 g/day) |
|
Experimentell: Intervention Group (T₂)
high-dose foxtail millet muffin (T₁; 100 g/day) |
high-dose foxtail millet muffin (T₂; 100 g/day) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
bmi
Tidsram: 10 weeks
|
Body mass index (BMI) was calculated as body weight (kg) divided by the square of height (m²) and expressed in kg/m². |
10 weeks
|
|
HBA1c
Tidsram: 10 weeks
|
Glycated hemoglobin (HbA1c) was measured to assess average blood glucose levels over the preceding 2-3 months and expressed as a percentage (%). |
10 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
LIPID PROFILE
Tidsram: 10 WEEKS
|
Lipid profile, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), was assessed and expressed in mg/dL. |
10 WEEKS
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- REC-UOL-/586/11/24
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .